New pharmacy player has big plans

Share this article:
A start-up institutional pharmacy company could soon become the market's No. 3 player, according to its executives. The parent group of Golden Living officially launched AlixaRx with predictions it could become a $250 million per year business within 18 months. Ultimately capturing one-fifth or more of the 16,000-nursing home market is a distinct possibility, said AlixaRx President Larry Deans: “If we had 20% of market share [within five years], right now that would be a good goal to shoot for. We believe providers have a need for this service.” AlixaRx's unveiling comes at the detriment of PharMerica, which is losing the Golden Living contracts, company officials said. PharMerica currently has about 20% of the long-term care institutional pharmacy market, which has put it second behind leader Omnicare, which commands approximately 60% of the market, Deans said.
Share this article:

More in Products

Nurse technology contest seeks applications

Nurses who want to share the ways technology has led to a better student or patient outcome are invited to enter a contest that touts two $10,000 cash awards.

Accessory for swimming approved for cochlear implants

Accessory for swimming approved for cochlear implants ...

The Food and Drug Administration has approved the Aqua+ accessory, a waterproof, behind-the-ear product for cochlear implant recipients. The accessory allows Cochlear™ Nucleus® 5 and Nucleus 6 Implant recipients2 to ...

Non-Invasive Open Ventilation System approved

Non-Invasive Open Ventilation System approved

Breathe Technologies, which makes the Non-Invasive Open Ventilation (NIOV) System, said the Food and Drug Administration has granted the fifth 510(k) clearance for the product.